Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent ...

Recursion Pharmaceuticals faces a 57% stock drop amid drug setbacks, rising cash burn, and AI discovery doubts. Learn more ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Swiss pharma company Roche (ROG.SW, RHHBY) is warning that its investment into the US could be at risk due to President Trump ...

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

President Donald Trump says he’ll sign an executive order on Monday intended to lower the cost of drugs in the U.S.

Foghorn Therapeutics Inc.’s FHTX share price has surged by 5.95%, which has investors questioning if this is right time to sell.

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

Donald Trump's order also directs the government to consider facilitating direct-to-consumer purchasing programs that would sell drugs at the prices other countries pay.

Global pharmaceutical stocks dropped sharply Monday after former U.S. President Donald Trump pledged to cut prescription drug ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...